Xarelto, also known by its generic name rivaroxaban, is not expected to go fully generic in 2024 [1]. While some patent expiries have occurred and are occurring, the situation is complex due to multiple patents and ongoing legal challenges [2].
When are Xarelto's Patents Actually Expiring?
The primary patents for Xarelto have expired or are nearing expiration. However, the manufacturer, Bayer, has obtained secondary patents that extend the drug's market exclusivity beyond the initial patent term [2]. These secondary patents cover specific aspects like manufacturing processes and formulations [2]. For instance, some key patents for rivaroxaban have already expired, but the latest patents related to its formulation and use are set to expire later [1]. According to DrugPatentWatch.com, the latest patent expiration for Xarelto is expected around 2030 [1].
What Happens if Xarelto Goes Generic?
When a brand-name drug goes generic, lower-cost versions manufactured by other companies can enter the market. This typically leads to a significant decrease in the drug's price, making it more accessible to patients and reducing healthcare costs [3]. Generic drugs are bioequivalent to their brand-name counterparts, meaning they have the same active ingredient, dosage, safety, and effectiveness [3].
Can Biosimilars Be Made for Xarelto?
Xarelto is a small molecule drug, not a biologic. Therefore, biosimilars are not applicable. Instead, generic versions of small molecule drugs like Xarelto are created [4].
Who is Developing Generic Versions of Xarelto?
Several pharmaceutical companies are developing generic versions of rivaroxaban. These include companies like Teva Pharmaceuticals, Accord Healthcare, and Hikma Pharmaceuticals, among others [2].
What is the Current Status of Xarelto Patent Litigation?
There have been numerous patent litigations surrounding Xarelto. Bayer has actively defended its secondary patents, leading to legal battles with generic manufacturers seeking to market their versions of rivaroxaban [2]. These challenges often aim to invalidate or find non-infringing pathways around Bayer's later-expiring patents [2].
How Does Xarelto Work?
Xarelto (rivaroxaban) is an anticoagulant that works by inhibiting Factor Xa, a crucial enzyme in the blood clotting cascade [5]. By blocking Factor Xa, it reduces thrombin generation, thereby preventing the formation of blood clots [5].
What Conditions Does Xarelto Treat?
Xarelto is prescribed to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [6].
What Are the Risks and Side Effects of Xarelto?
The most significant risk associated with Xarelto, like other anticoagulants, is bleeding [7]. Side effects can range from mild bruising to severe, life-threatening hemorrhages [7]. Other potential side effects include dizziness, nausea, and abdominal pain [7].
How Does Xarelto Compare to Warfarin?
Xarelto is a direct oral anticoagulant (DOAC) and is often compared to warfarin, a vitamin K antagonist [8]. Unlike warfarin, Xarelto does not typically require regular blood monitoring or dietary restrictions [8]. It generally has a more predictable anticoagulant effect and fewer drug-drug interactions than warfarin [8].
---
Sources
1. https://drugpatentwatch.com/drugs/rivaroxaban
2. Information on patent expiry and litigation for Xarelto (rivaroxaban) has been publicly reported by various pharmaceutical news outlets and legal analysis sites.
3. Information regarding the general impact of generic drug entry on pricing and accessibility is widely available from regulatory bodies and healthcare economics resources.
4. Distinction between biosimilars and generics is a standard concept in pharmaceutical regulation.
5. Mechanism of action for rivaroxaban is detailed in its prescribing information and medical literature.
6. Indications for Xarelto are available in its official prescribing information.
7. Risks and side effects of Xarelto are detailed in its prescribing information and patient information leaflets.
8. Comparisons between Xarelto and warfarin are commonly found in clinical guidelines and medical reviews of anticoagulants.